DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Endroit courant :
> This Story

Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment




Molecular Imaging Homepage

Siemens showcases works in progress at SNMMI Includes TeamPlay, syngo Virtual Cockpit and a number of AI algorithms

First dual PET isotope scans performed on living organism Discussed at SNMMI 2019 Annual Meeting

MiE showcases cardiac PET scanner, Ancoris, at SNMMI Provides simultaneous 3D cardiac PET perfusion and CFR

Software innovations for patient-specific theranostics and molecular radiotherapy Trends that will impact the future of medicine

Philips shares insights on PET/CT utilization trends at SNMMI Continued growth in use expected through 2019

GE debuts Discovery IQ Gen 2 PET/CT system at SNMMI Equipped with MotionFree to prevent blurring of images

Rethinking training and education for the future of medicine at SNMMI Discussing innovations and efforts of SNMMI Technologist Section

Theranostics continue to gain momentum Investments ramp up but challenges remain

SNMMI Product Showcase Don't miss these solutions on the exhibit floor

Mobile PET relieves hardship for rural cancer patients Mobile PET isn't just good medicine, it's good business

SHINE Medical Technologies has
secured the rights for an approach
that will enhance Lu-177 production
from IOCB Prague (Photo courtesy of

SHINE secures rights to new method for Lutetium-177 production

par John R. Fischer , Staff Reporter
SHINE Medical Technologies has secured the rights from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague) to utilize an approach that will enhance production of Lutetium-177.

The method, which enables the separation of rare earth elements, will enable the Wisconsin-based enterprise to generate the radioisotope for cancer treatment at greater speed and scale, as outlined in the property license agreement signed between SHINE and IOCB Prague.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

"Chemical separation of Lu-177 from irradiated ytterbium matrix is currently a major bottleneck in Lu-177 production," Dr. Miloslav Polášek, head of the Coordination Chemistry Research Group at IOCB Prague, told HCB News. "The new technology has the potential to both shorten the separation time and increase the scale. Overall production rate increase by a factor of 10 or more is possible with this new method. This will be a matter of further development."

Separating rare earth elements is a difficult task, particularly when they are radioactive and must be extremely pure.

The IOCB separation method will enable SHINE to quickly and efficiently separate Lu-177 from irradiated ytterbium-176 targets to produce a highly concentrated Lu-177 product called “non-carrier-added” or “high-specific activity” Lu-177. Such a form is essentially free of stable isotopes of lutetium.

It will be used with SHINE’s platform technology, which uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies for producing medical isotopes. These include no reliance on a nuclear reactor, the use of less electricity, less waste generation, and compatibility with the nation's existing supply chain for molybdenum-99, the parent isotope of the medical radioisotope, technetium-99m.

The method by IOCB Prague can be applied to the separation of more than one metal radionuclide, providing the potential for greater production of radioisotopes that can be applied to medical diagnostics and treatments.

"The method can also be used to separate other metal radionuclides, provided that their chemical properties are compatible with the process," said Polášek. "For the cases where the separation step is the limiting factor, the new technology could indeed help increase availability of such a radionuclide."

In addition to adopting the new method, SHINE plans to create its own ytterbium-176 starting material and is in the midst of expanding its presence, having broken ground this month on its first U.S. medical isotope facility in Janesville, Wisconsin.

SHINE was unable to comment.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

La publicité d'email
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Voir les utilisateurs récemment certifiés
Voir les utilisateurs récemment certifiés
Récemment évalué sur DOTmed
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service Technicians Forum
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2019, Inc.